A. Bono

2.7k total citations · 2 hit papers
19 papers, 1.9k citations indexed

About

A. Bono is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, A. Bono has authored 19 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Surgery, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in A. Bono's work include Bladder and Urothelial Cancer Treatments (8 papers), Prostate Cancer Treatment and Research (6 papers) and Hormonal and reproductive studies (3 papers). A. Bono is often cited by papers focused on Bladder and Urothelial Cancer Treatments (8 papers), Prostate Cancer Treatment and Research (6 papers) and Hormonal and reproductive studies (3 papers). A. Bono collaborates with scholars based in Italy, Belgium and Canada. A. Bono's co-authors include Richard Sylvester, Walter Albrecht, Eila C. Skinner, Hendrik Van Poppel, Thomas E. Keane, L. Da Pozzo, Laurence Klotz, Vsevolod Matveev, Jean-Marie Maréchal and Sandra Collette and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Journal of Urology.

In The Last Decade

A. Bono

19 papers receiving 1.9k citations

Hit Papers

A Prospective Randomized EORTC Intergroup Phase 3 Study C... 2006 2026 2012 2019 2006 2010 250 500 750

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Bono Italy 12 1.5k 996 803 189 172 19 1.9k
Laurent Zini France 26 1.1k 0.7× 783 0.8× 781 1.0× 175 0.9× 274 1.6× 47 1.7k
Philippe Arjane Canada 26 988 0.7× 460 0.5× 871 1.1× 220 1.2× 166 1.0× 47 1.6k
Roberto Bertini Italy 29 2.0k 1.3× 861 0.9× 890 1.1× 232 1.2× 278 1.6× 120 2.4k
Homayoun Zargar United States 32 2.1k 1.4× 829 0.8× 1.1k 1.4× 240 1.3× 88 0.5× 123 2.8k
Jean-Marie Maréchal France 7 1.8k 1.2× 626 0.6× 444 0.6× 140 0.7× 160 0.9× 11 2.0k
Rodolphe Thuret France 27 1.3k 0.8× 479 0.5× 1.0k 1.3× 458 2.4× 180 1.0× 109 2.2k
P. Mongiat-Artus France 23 876 0.6× 310 0.3× 515 0.6× 309 1.6× 176 1.0× 119 1.6k
Alp Tuna Beksaç United States 18 917 0.6× 311 0.3× 367 0.5× 126 0.7× 88 0.5× 82 1.1k
Humberto Villavicencio Spain 29 671 0.4× 385 0.4× 1.5k 1.8× 232 1.2× 95 0.6× 90 2.1k
Guilherme Godoy United States 29 1.5k 1.0× 551 0.6× 1.4k 1.7× 285 1.5× 120 0.7× 86 2.7k

Countries citing papers authored by A. Bono

Since Specialization
Citations

This map shows the geographic impact of A. Bono's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Bono with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Bono more than expected).

Fields of papers citing papers by A. Bono

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Bono. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Bono. The network helps show where A. Bono may publish in the future.

Co-authorship network of co-authors of A. Bono

This figure shows the co-authorship network connecting the top 25 collaborators of A. Bono. A scholar is included among the top collaborators of A. Bono based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Bono. A. Bono is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Silva, Fernando Calais da, et al.. (2011). 716 PHASE III STUDY OF INTERMITTENT MAB VS CONTINUOS MAB. The Journal of Urology. 185(4S). 2 indexed citations
2.
Poppel, Hendrik Van, L. Da Pozzo, Walter Albrecht, et al.. (2010). A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology. 59(4). 543–552. 698 indexed citations breakdown →
3.
Bono, A., et al.. (2010). Tuning an Earthworm phase picker: some considerations on the pick_ew parameters. 7 indexed citations
4.
Poppel, Hendrik Van, L. Da Pozzo, Walter Albrecht, et al.. (2006). A Prospective Randomized EORTC Intergroup Phase 3 Study Comparing the Complications of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. European Urology. 51(6). 1606–1615. 764 indexed citations breakdown →
5.
Bono, A., et al.. (2006). Phase III intermittent MAB vs continuous MAB. Journal of Clinical Oncology. 24(18_suppl). 4513–4513. 20 indexed citations
6.
Bono, A., et al.. (2006). PHASE III STUDY OF INTERMITTENT MAB VERSUS CONTINUOUS MAB - AN INTERNATIONAL COOPERATIVE STUDY - QUALITY OF LIFE. European Urology Supplements. 5(2). 289–289. 6 indexed citations
7.
Meijden, Adrian van der, R. Sylvester, W. Oosterlinck, et al.. (2003). Maintenance bacillus calmette-guerin for TA, T1 bladder cancer is not associated with increased toxicity, results from an eortc genito-urinary group phase III trial. European Urology Supplements. 2(1). 190–190. 4 indexed citations
8.
Ciaccio, Marcello, et al.. (2003). Aminoacid profile and oxidative status in children affected by Down syndrome before and after supplementary nutritional treatment.. PubMed. 52(2). 72–9. 11 indexed citations
9.
Richie, Jerome P., et al.. (1998). Tumor, nodes, metastasis (TNM) classification of bladder cancer. Urologic Oncology Seminars and Original Investigations. 4(4-5). 90–93. 2 indexed citations
10.
Bouffioux, C, K. H. Kurth, A. Bono, et al.. (1995). Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma : results of 2 european organization for research and treatment of cancer randomized trials with Mitomycin C and Doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. The Journal of Urology. 153(3). 934–941. 98 indexed citations
12.
Keuppens, F., Peter Whelan, D.W.W. Newling, et al.. (1993). Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853). Cancer. 72(S12). 3863–3869. 19 indexed citations
13.
Zurrida, Stefano, et al.. (1992). Mondor's disease and breast cancer. Cancer. 69(9). 2267–2270. 89 indexed citations
14.
Jakse, G., R R Hall, A. Bono, et al.. (1992). BCG treatment in Tis of the urinary bladder, results of the EORTC Protocol 30861. EORTC GU Group.. PubMed. 378. 69–74. 2 indexed citations
15.
Denis, L., Philip Smith, Jandeilson L. Moura, et al.. (1991). Total Androgen Ablation: European Experience. Urologic Clinics of North America. 18(1). 65–73. 15 indexed citations
16.
Denis, L., Philip H. Smith, A. Bono, et al.. (1990). Orchidectomy vs. Zoladex plus Flutamide in Patients withMetastatic Prostate Cancer. European Urology. 18(3). 34–40. 16 indexed citations
17.
Bartoli, Cesare, Stefano Zurrida, Paolo Veronesi, et al.. (1990). Small sized phyllodes tumor of the breast.. PubMed. 16(3). 215–9. 15 indexed citations
18.
Denis, L., et al.. (1989). Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group.. PubMed. 303. 129–43. 5 indexed citations
19.
Ph, Smith, et al.. (1977). The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil.. PubMed. 3(5). 276–8. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026